About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a company based in Shanghai (China) founded in 2009.. Innovative Cellular Therapeutics has raised $97.13 million across 3 funding rounds from investors including CDH, LH Ventures and Volcanics. Innovative Cellular Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others.
- Headquarter Shanghai, China
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$97.13 M (USD)
in 3 rounds
-
Latest Funding Round
$40 M (USD), Series C
Sep 06, 2021
-
Investors
CDH
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Innovative Cellular Therapeutics
Innovative Cellular Therapeutics has successfully raised a total of $97.13M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $40 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $40.0M
-
First Round
First Round
(24 Apr 2018)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Series C - Innovative Cellular Therapeutics | Valuation | CDH |
|
| Dec, 2019 | Amount | Series B - Innovative Cellular Therapeutics | Valuation | LH Ventures |
|
| Apr, 2018 | Amount | Series B - Innovative Cellular Therapeutics | Valuation | Volcanics Venture , ShenZhen GTJA Investment Group |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Innovative Cellular Therapeutics
Innovative Cellular Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include CDH, LH Ventures and Volcanics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and private debt firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investment services are offered by Volcanics to clients.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Innovative Cellular Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Innovative Cellular Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Innovative Cellular Therapeutics Comparisons
Competitors of Innovative Cellular Therapeutics
Innovative Cellular Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Innovative Cellular Therapeutics
Frequently Asked Questions about Innovative Cellular Therapeutics
When was Innovative Cellular Therapeutics founded?
Innovative Cellular Therapeutics was founded in 2009 and raised its 1st funding round 9 years after it was founded.
Where is Innovative Cellular Therapeutics located?
Innovative Cellular Therapeutics is headquartered in Shanghai, China.
Who is the current CEO of Innovative Cellular Therapeutics?
Lei Xiao is the current CEO of Innovative Cellular Therapeutics.
Is Innovative Cellular Therapeutics a funded company?
Innovative Cellular Therapeutics is a funded company, having raised a total of $97.13M across 3 funding rounds to date. The company's 1st funding round was a Series B of $28.53M, raised on Apr 24, 2018.
What does Innovative Cellular Therapeutics do?
Innovative Cellular Therapeutics was founded in 2009 in Shanghai, China, within the biotechnology sector. CAR-T cell therapies are developed for treating blood cancers and solid tumors. A CoupledCAR technology platform is employed to advance a pipeline of drug candidates targeting colorectal, thyroid, pancreatic, and lung cancers. Operations focus on innovative cellular treatments, led by CEO Lei Xiao.
Who are the top competitors of Innovative Cellular Therapeutics?
Innovative Cellular Therapeutics's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.